Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.

Florescu, Diana F; Keck, Megan A

Florescu, Diana F; Keck, Megan A.

Affiliation

Florescu DF; Transplant Infectious Diseases Program, University of Nebraska Medical Center, Omaha, NE 68198-5400, USA.

Expert Rev Anti Infect Ther ; 12(10): 1171-8, 2014 Oct.

Article in En | MEDLINE | ID: mdl-25120093

Subject(s)

Antiviral Agents/therapeutic use; Cytosine/analogs & derivatives; DNA Virus Infections/drug therapy; Organophosphonates/therapeutic use; Adenoviridae/drug effects; Antiviral Agents/chemistry; Antiviral Agents/pharmacology; Cytomegalovirus/drug effects; Cytosine/chemistry; Cytosine/pharmacology; Cytosine/therapeutic use; Humans; Microbial Sensitivity Tests; Molluscum contagiosum virus/drug effects; Organophosphonates/chemistry; Organophosphonates/pharmacology; Orthopoxvirus/drug effects; Polyomavirus/drug effects

Key words

BK virus; Brincidofovir; CMX001; JC virus; adenovirus; cytomegalovirus; dsDNA virus; molluscum; orthopoxvirus; vaccinia virus

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Plantas_medicinales Main subject: Antiviral Agents / Cytosine / DNA Virus Infections / Organophosphonates Language: En Journal: Expert Rev Anti Infect Ther Year: 2014 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google